ACT receives patent for its single-blastomere technology Advanced Cell Technology.

ACT receives patent for its single-blastomere technology Advanced Cell Technology, Inc. , a innovator in neuro-scientific regenerative medicine, announced today that it has been issued a patent on its single-blastomere technique. The single-blastomere technology uses a one-cell biopsy approach identical to pre-implantation genetic analysis , which is widely used in the in vitro fertilization procedure and does not hinder the embryo’s developmental potential.D., chief scientific officer of Action, said, This patent issuance represents recognition of the innovation underlying our single-blastomere technology.Vitamin D deficiency can cause rickets in children or a bone-softening condition called osteomalacia and muscle tissue weakness in adults. Related StoriesScientific consensus paper highlights health advantages of UV exposure and supplement DVitamin D insufficiency puts people at risk of developing heart problemsStudy displays vitamin D, supplements fail to drive back colorectal cancer In a double-blind research that gave varying vitamin D doses to African-American and Caucasian women of identical body size, levels of the 25OHD biomarker were very similar. The findings suggest that vitamin D absorption and metabolism is the same in both combined groups.